US › Healthcare

Tela Bio Inc (TELA)

US · Healthcare · Medical Devices

$1.29+9.32%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$19.3M

Revenue YoY

-4.5%

Net profit

$-11.3M

EPS

$-0.20

EPS estimate

$-0.17

Net margin

-58.4%

EPS came in at -0.20 against a street estimate of -0.17 — a miss of 17.6%.

Key statistics

Market cap

$49.2M

Forward P/E

0.0

P/B

7.30

Book value

$-0.35

EPS (TTM)

$-0.82

52-week high

$1.69

52-week low

$0.50

50-day MA

$0.76

200-day MA

$0.86

Beta

1.36

Analyst view

Analysts rate Tela Bio Inc a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $2.10.

Shareholding

Insiders

9.10%

Institutions

65.91%

Largest institutional holders

Fund	Stake
Essex Woodlands Health Ventures	17.18%
Nantahala Capital Management, LLC	11.46%
Stonepine Capital Management Llc	5.83%
SILVERARC CAPITAL MANAGEMENT, LLC	5.03%
Vanguard Capital Management, LLC	3.43%
Dafna Capital Management LLC	3.21%
Perkins Capital Management Inc	3.16%
UBS Group AG	2.36%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tela Bio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.